Stockscreener 앱 받기
10.03
7.81%
-0.85
시간 외 거래:
10.03
Celcuity Inc 주식(CELC)의 최신 뉴스
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights By Investing.com - Investing.com South Africa
Celcuity at Leerink Global Healthcare Conference: Promising Cancer Drug Insights - Investing.com Canada
BlackRock, Inc. Expands Holdings with Celcuity Inc. Acquisition - GuruFocus.com
Rhumbline Advisers Boosts Position in Celcuity Inc. (NASDAQ:CELC) - Defense World
(CELC) Technical Data - Stock Traders Daily
Brokerages Set Celcuity Inc. (NASDAQ:CELC) Target Price at $30.17 - Defense World
Celcuity, Inc. to Host Earnings Call - ACCESS Newswire
New York State Common Retirement Fund Purchases 3,682 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - Quantisnow
(CELC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Celcuity stock touches 52-week low at $10.35 amid market challenges - Investing.com India
Celcuity stock touches 52-week low at $10.35 amid market challenges By Investing.com - Investing.com South Africa
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences - The Manila Times
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January - MarketBeat
Celcuity Set to Join Russell 2000 and 3000 Indexes - ACCESS Newswire
Celcuity’s High-Stakes Oncology Bet Is Underappreciated (NASDAQ:CELC) - Seeking Alpha
Q1 Earnings Forecast for Celcuity Issued By Leerink Partnrs - MarketBeat
Bleakley Financial Group LLC Acquires Shares of 11,159 Celcuity Inc. (NASDAQ:CELC) - Defense World
Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts - MarketBeat
Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - MarketBeat
Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs - Defense World
Celcuity Inc. (NASDAQ:CELC) Receives $30.17 Consensus Price Target from Brokerages - Defense World
Scorpion stinger bringer of more PI3Kα inhibitor deals? - BioWorld Online
JPMorgan Chase & Co. Sells 11,612 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference - ACCESS Newswire
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates - ACCESS Newswire
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer - ACCESS Newswire
When (CELC) Moves Investors should Listen - Stock Traders Daily
Jefferies lifts Celcuity stock target to $33, maintains Buy rating - MSN
Jefferies lifts Celcuity stock target to $33, maintains Buy rating By Investing.com - Investing.com Australia
Celcuity Closes $100 Million Private Placement - ACCESS Newswire
Celcuity Inc. Announces $50 Million Private Placement - ACCESS Newswire
Hennion & Walsh Asset Management Inc. Buys 71,006 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Analysts - Defense World
Celcuity Inc. (NASDAQ:CELC) Holdings Raised by Barclays PLC - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Bought by Barclays PLC - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Brokerages - MarketBeat
Analyzing Celcuity (NASDAQ:CELC) and CannLabs (OTCMKTS:CANL) - Defense World
1.39%
0.55%
자본화:
|
볼륨(24시간):